OPT 0.62% 40.8¢ opthea limited

CATT of course tested ranibizumab (Lucentis) as the control...

  1. 107 Posts.
    lightbulb Created with Sketch. 88
    CATT of course tested ranibizumab (Lucentis) as the control against bevacizumab (Avastin) and not aflibercept (Eylea) against bevacizumab (Lucentis).

    Apologies. I was too late to edit my above post.
 
watchlist Created with Sketch. Add OPT (ASX) to my watchlist
(20min delay)
Last
40.8¢
Change
0.003(0.62%)
Mkt cap ! $504.7M
Open High Low Value Volume
41.5¢ 41.5¢ 40.0¢ $233.0K 571.7K

Buyers (Bids)

No. Vol. Price($)
8 258387 40.5¢
 

Sellers (Offers)

Price($) Vol. No.
41.0¢ 74069 5
View Market Depth
Last trade - 12.00pm 26/07/2024 (20 minute delay) ?
OPT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.